Biohaven Pharmaceutical Holding Operating Margin 2016-2022 | BHVN

Current and historical operating margin for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current operating profit margin for Biohaven Pharmaceutical Holding as of March 31, 2022 is -94.64%.
Biohaven Pharmaceutical Holding Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2022-03-31 $0.74B $-0.52B -70.87%
2021-12-31 $0.46B $-0.71B -152.27%
2021-09-30 $0.31B $-0.72B -233.44%
2021-06-30 $0.19B $-0.74B -390.53%
2021-03-31 $0.11B $-0.73B -683.18%
2020-12-31 $0.06B $-0.65B -1009.38%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00